Assembly Biosciences, Inc. (ASMB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Assembly Biosciences reported revenue of $72.3M, up 153.5% from $28.5M the year before. Net income was -$6.1M (a -8.5% net margin), or -$0.55 per diluted share. Operating margin was -16.8%. Operating activities generated -$41.1M of cash, leaving -$41.2M of free cash flow. At fiscal year end, Assembly Biosciences held $257.6M in total assets against $50.8M in total liabilities, including $58.5M of cash and equivalents.
Open the full interactive Assembly Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Assembly Biosciences Key Stats
| Share Price | $20.34 |
|---|---|
| Market Cap | $383.5M |
| Revenue YoY Growth | +153.5% |
| 52-Week Range | $20.34 – $38.50 |
| Shares Outstanding | 18.9 million (basic, 2026 Q2) |
Assembly Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $79.1M | $6.3M | $0 | $7.2M | $28.5M | $72.3M |
| Operating Income | -$64.8M | -$132.7M | -$94.1M | -$64.6M | -$45.4M | -$12.1M |
| Pre-Tax Income | -$62.2M | -$132.4M | -$93.1M | -$61.2M | -$39.8M | -$6.1M |
| Income Tax | — | -$2.5M | $0 | $33,000 | $330,000 | $0 |
| Net Income | -$62.2M | -$129.9M | -$93.1M | -$61.2M | -$40.2M | -$6.1M |
| Diluted EPS | -$13.32 | -$36.00 | -$23.04 | -$13.38 | -$6.69 | -$0.55 |
Assembly Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $10.8M | $42.5M | $8.2M | $13.4M |
| Net Income | -$9.2M | $22.1M | -$9.1M | -$3.9M |
| Diluted EPS | -$0.72 | $1.97 | -$0.54 | -$0.20 |
Assembly Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $59.4M | $45.6M | $52.4M | $19.8M | $38.3M | $58.5M |
| Current Assets | $224.5M | $154.2M | $97.0M | $133.8M | $115.5M | $254.5M |
| Total Assets | $283.3M | $191.1M | $101.8M | $136.8M | $119.2M | $257.6M |
| Current Liabilities | $24.4M | $16.1M | $16.3M | $39.2M | $47.8M | $48.8M |
| Total Liabilities | $42.7M | $22.1M | $19.1M | $95.7M | $85.8M | $50.8M |
| Shareholders' Equity | $240.6M | $168.9M | $82.7M | $41.1M | $33.4M | $206.8M |
Assembly Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$63.0M | -$93.4M | -$84.5M | $22.7M | -$51.1M | -$41.1M |
| Cash From Investing | $68.1M | $26.5M | $90.6M | -$69.1M | $40.2M | -$113.5M |
| Cash From Financing | $7.6M | $53.1M | $614,000 | $13.8M | $29.4M | $174.7M |
| Free Cash Flow | -$63.4M | -$96.5M | -$84.6M | $22.5M | -$51.1M | -$41.2M |
Figures from Assembly Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Assembly Biosciences financials page for every line item.
Assembly Biosciences Company Profile
| Ticker | ASMB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001426800 |
Frequently Asked Questions
What was Assembly Biosciences' revenue in fiscal 2025?
Assembly Biosciences (ASMB) reported revenue of $72.3M for fiscal 2025.
What is Assembly Biosciences' annual revenue history?
Assembly Biosciences' annual revenue by fiscal year: 2020: $79.1M; 2021: $6.3M; 2022: $0; 2023: $7.2M; 2024: $28.5M; 2025: $72.3M.
What was Assembly Biosciences' net income in fiscal 2025?
Assembly Biosciences reported net income of -$6.1M for fiscal 2025.
What was Assembly Biosciences' earnings per share (EPS) in fiscal 2025?
Assembly Biosciences' diluted EPS was -$0.55 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Assembly Biosciences generate in fiscal 2025?
Assembly Biosciences generated -$41.2M of free cash flow in fiscal 2025.
What was Assembly Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Assembly Biosciences reported revenue of $13.4M.
How many shares of Assembly Biosciences are outstanding?
Assembly Biosciences reported a weighted average of 18.9 million basic shares outstanding in 2026 Q2.
What is Assembly Biosciences' market cap?
Based on its latest closing price, Assembly Biosciences (ASMB) has a market capitalization of about $383.5M.
When does Assembly Biosciences' fiscal year end?
Assembly Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Assembly Biosciences headquartered?
Assembly Biosciences lists its business address in South San Francisco, California in its SEC filings.